{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:56:20Z","timestamp":1760057780292,"version":"build-2065373602"},"reference-count":13,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: This study presents a young man with hereditary spherocytosis (HS) who underwent intensive chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and achieved complete remission. This case challenges the idea of HS as a barrier to standard DLBCL treatment. Discussion: By meticulously monitoring blood counts and providing timely transfusions, the team successfully mitigated potential complications associated with chemotherapy-induced stress on red blood cells. Conclusions: This experience underscores the importance of a multidisciplinary approach and tailored treatment plans for patients with co-existing conditions, suggesting that HS should not automatically disqualify them from potentially curative therapies for aggressive lymphomas.<\/jats:p>","DOI":"10.3390\/hematolrep17020011","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:36:47Z","timestamp":1740375407000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Intensive Chemotherapy in Hereditary Spherocytosis"],"prefix":"10.3390","volume":"17","author":[{"given":"Carrai","family":"Valentina","sequence":"first","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0411-9962","authenticated-orcid":false,"given":"Giubbilei","family":"Cristina","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciceri","family":"Manuel","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u2019Angelo","family":"Simona","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassi","family":"Luca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sordi","family":"Benedetta","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Vannucchi","family":"Alessandro Maria","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"},{"name":"Center for Research and Innovation in Myeloproliferative Neoplasms, Hematology Unit, Careggi University Hospital, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puccini","family":"Benedetta","sequence":"additional","affiliation":[{"name":"Hematology Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"ref_1","unstructured":"Zamora, E.A., and Schaefer, C.A. (2023). Hereditary Spherocytosis. StatPearls, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2004.05052.x","article-title":"Guidelines for the diagnosis and management of hereditary spherocytosis","volume":"126","author":"Stevens","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.21037\/atm.2018.07.35","article-title":"Old and new insights into the diagnosis of hereditary spherocytosis","volume":"6","author":"Ciepiela","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3324\/haematol.2016.161166","article-title":"Recommendations regarding splenectomy in hereditary hemolytic anemias","volume":"102","author":"Iolascon","year":"2017","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3476(05)81081-9","article-title":"Variable clinical severity of hereditary spherocytosis: Relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis","volume":"117","author":"Eber","year":"1990","journal-title":"J. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100750","DOI":"10.1016\/j.esmoop.2022.100750","article-title":"How I treat diffuse large B-cell lymphoma","volume":"8","author":"Melchardt","year":"2023","journal-title":"ESMO Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ejh.12321","article-title":"The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: A single centre\u2019s experience","volume":"93","author":"Morrison","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(08)61588-3","article-title":"Hereditary spherocytosis","volume":"372","author":"Perrotta","year":"2008","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0897190014546108","article-title":"Antineoplastic Agents and the Associated Myelosuppressive Effects: A Review","volume":"27","author":"Barreto","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_11","unstructured":"Hanoodi, M., and Mittal, M. (2024). Methotrexate. StatPearls, StatPearls Publishing."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/1535370219853791","article-title":"Vincristine-induced anemia in hereditary spherocytosis","volume":"244","author":"Michlitsch","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e18266","DOI":"10.1097\/MD.0000000000018266","article-title":"Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report","volume":"98","author":"Qian","year":"2019","journal-title":"Medicine"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/2\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:08Z","timestamp":1760028068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/2\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["hematolrep17020011"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17020011","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}